Boao Biotech Ltd - 25 Jan 2024 Form 4 Insider Report for Yubo International Biotech Ltd (YBGJ)

Role
10%+ Owner
Signature
/s/ Yulin Cao as sole Director of Boao Biotech Ltd., for and on behalf of Boao Biotech Ltd.
Issuer symbol
YBGJ
Transactions as of
25 Jan 2024
Net transactions value
-$1,512,042
Form type
4
Filing time
03 Jun 2025, 15:23:24 UTC

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Boao Biotech Ltd 10%+ Owner C/O WICKHAMS CAY II, P.O. BOX 2221, ROAD TOWN, TORTOLA, VIRGIN ISLANDS, BRITISH /s/ Yulin Cao as sole Director of Boao Biotech Ltd., for and on behalf of Boao Biotech Ltd. 03 Jun 2025 0001841399
CAO YULIN 10%+ Owner C/O WICKHAMS CAY II, P.O. BOX 2221, ROAD TOWN, TORTOLA, VIRGIN ISLANDS, BRITISH /s/ Yulin Cao 03 Jun 2025 0002067350

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YBGJ Class A Common Stock Sale $150,000 -500,000 -2% $0.3000 24,467,800 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $222,456 -741,521 -3% $0.3000 23,726,279 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $90,510 -301,701 -1.3% $0.3000 23,424,578 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $109,305 -364,351 -1.6% $0.3000 23,060,227 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $54,377 -181,256 -0.79% $0.3000 22,878,971 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $26,069 -86,897 -0.38% $0.3000 22,792,074 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $127,996 -426,654 -1.9% $0.3000 22,365,420 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $617,276 -2,057,586 -9.2% $0.3000 20,307,834 25 Jan 2024 Direct
transaction YBGJ Class A Common Stock Sale $114,052 -380,174 -1.9% $0.3000 19,927,660 25 Jan 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

The shares of Class A Common Stock of the Issuer are held directly by Boao Biotech Ltd. Mr. Yulin Cao is the sole Director of Boao Biotech Ltd, and as such, Mr. Yulin Cao may be deemed to have voting and investment power over the shares of Class A Common Stock held by Boao Biotech Ltd. Mr. Yulin Cao disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (Section 16), except to the extent of his indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.